CSF1R and early-onset autosomal dominant Alzheimer disease: Indeed, microglial depletion using the pharmacological receptor tyrosine kinase inhibitor of CSF1R (Colony stimulating factor 1 receptor, also known as cFMS) and related kinases, PLX3397 or PLX5622, in EAE (reviewed in [19]) and in Alzheimer’s disease models [20,21,22] reduces neuroinflammation and supports remyelination and recovery [23].